Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response

NEW BRUNSWICK, N.J., July 1, 2021 – Johnson& Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials